Sugi Predict

Sugi Predict / Targets / PLD1

PLD1

Phospholipase D1 · Q13393 · PLD1 on Sugi Atlas →

12,707 patent compounds predicted against PLD1, 8,037 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Halopemide Halopemide (SCHEMBL121267) 1.00 18/20
SCHEMBL795275 SCHEMBL795275 0.47 15/20
SCHEMBL794432 SCHEMBL794432 0.45 14/20
SCHEMBL788338 SCHEMBL788338 0.41 14/20
SCHEMBL798610 SCHEMBL798610 0.49 13/20
SCHEMBL793278 SCHEMBL793278 0.48 13/20
SCHEMBL787981 SCHEMBL787981 0.46 13/20
SCHEMBL806210 SCHEMBL806210 0.44 13/20
SCHEMBL796066 SCHEMBL796066 0.41 13/20
SCHEMBL795350 SCHEMBL795350 0.40 13/20
SCHEMBL793910 SCHEMBL793910 0.53 12/20
SCHEMBL788077 SCHEMBL788077 0.49 12/20
SCHEMBL793985 SCHEMBL793985 0.47 12/20
SCHEMBL788578 SCHEMBL788578 0.46 12/20
SCHEMBL794661 SCHEMBL794661 0.45 12/20
SCHEMBL788137 SCHEMBL788137 0.44 12/20
SCHEMBL806264 SCHEMBL806264 0.44 12/20
SCHEMBL788134 SCHEMBL788134 0.43 12/20
SCHEMBL794584 SCHEMBL794584 0.49 11/20
SCHEMBL798569 SCHEMBL798569 0.48 11/20

Clinical trials — most relevant to PLD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A EARLY_PHASE1COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Supplemental Choline and Brain Development in Humans nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
PET Imaging of DHA Metabolism nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Molecular Markers of Human Sperm Function nanWITHDRAWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Candida Associated Cytokines in Oral Leukoplakia nanCOMPLETED
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans nanCOMPLETED
Activity of Essential Fatty Acid Elongation/Desaturation Pathway During Early Life in Human Infants, In Vivo nanCOMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLD1 binder may also engage these)

ProteinNameSimilarity
P70496 — 1.000 P70496 →
O08684 — 1.000 O08684 →
Q9Z280 — 1.000 Q9Z280 →
Q9M9W8 — 0.999 Q9M9W8 →
Q9C5Y0 — 0.996 Q9C5Y0 →
Q9LRZ5 — 0.993 Q9LRZ5 →
P70498 — 0.991 P70498 →
Q09706 — 0.990 Q09706 →
P97813 — 0.988 P97813 →
O82549 — 0.988 O82549 →
O04865 — 0.988 O04865 →
PLD2 Phospholipase D2 0.987 landscape →
Q9SSQ9 — 0.986 Q9SSQ9 →
P86387 — 0.985 P86387 →
O04883 — 0.985 O04883 →
Q43007 — 0.983 Q43007 →
Q43270 — 0.983 Q43270 →
Q38882 — 0.982 Q38882 →
P55939 — 0.982 P55939 →
P58766 — 0.982 P58766 →
Q41142 — 0.982 Q41142 →
Q0V8L6 — 0.981 Q0V8L6 →
Q4KWH8 — 0.981 Q4KWH8 →
Q6DNF7 — 0.980 Q6DNF7 →
Q9UHW9 — 0.980 Q9UHW9 →
Q8N7P1 — 0.980 Q8N7P1 →
Q5XHF8 — 0.979 Q5XHF8 →
H2KZM9 — 0.979 H2KZM9 →
Q6ZQB6 — 0.979 Q6ZQB6 →
Q6ZT07 — 0.979 Q6ZT07 →